US FDA Fast Tracks Antithrombotic from BMS and J&J
Johnson & Johnson and Bristol Meyer’s Squibb’s (BMS’s) antithrombotic milvexian has been fast tracked by the US Food and Drug Administration for three indications, according to the companies. The drug received the designation for the drug for stroke, atrial fibrillation, and acute coronary syndrome. Fast track designation is often granted for drugs that address medical conditions with limited treatment options.
Stroke Association Warns Over 47,000 Stroke Patients in England Could Lose Out on Life-Changing Treatment
A report by the Stroke Association notes that only 28% of eligible stroke patients in England received mechanical thrombectomy, a technique that can save lives and greatly reduce the disability caused by stroke. This number falls far short of NHS England’s goal of performing the procedure on all possible patients. During the operation, a blood clot is physically removed from cerebral blood vessels via a specialized catheter, avoiding some of the risks of the only other stroke treatment, tissue plasminogen activator.
